Cover Image
市場調查報告書

白細胞介素-6 (IL-6) 抑制劑的開發平台分析:臨床試驗&結果、專利、指定、聯盟、其他趨勢

Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

出版商 P&S Market Research Pvt. Ltd 商品編碼 600278
出版日期 內容資訊 英文 107 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
白細胞介素-6 (IL-6) 抑制劑的開發平台分析:臨床試驗&結果、專利、指定、聯盟、其他趨勢 Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments
出版日期: 2017年11月01日 內容資訊: 英文 107 Pages
簡介

本報告提供白細胞介素-6 (IL-6) 抑制劑的開發平台趨勢調查,各階段、分子類型、投藥途徑、企業的開發平台趨勢,藥物簡介,競爭環境,主要企業的基準,主要企業簡介等彙整。

第1章 調查背景

  • 調查目的
  • 市場定義
  • 調查範圍
  • 主要相關利益者

第2章 調查手法

  • 二次調查
  • 一次調查

第3章 摘要整理

第4章 開發平台的展望

  • 概要
  • 主要的成長推動因素
  • 主要的障礙
  • 開發平台分析
    • 各階段
    • 各分子類型
    • 各投藥途徑
    • 各企業

第5章 開發平台分析:各階段

  • 申請完畢:藥物簡介
    • 前臨床研究
    • 前臨床研究結果
    • 臨床試驗
    • 臨床結果
    • 策略性開發
    • 指定
    • 津貼
    • 專利
    • 技術
  • 第三階段:藥物簡介
    • 前臨床研究
    • 前臨床研究結果
    • 臨床試驗
    • 臨床結果
    • 策略性開發
    • 指定
    • 津貼
    • 專利
    • 技術
  • 第二階段:藥物簡介
    • 前臨床研究
    • 前臨床研究結果
    • 臨床試驗
    • 臨床結果
    • 策略性開發
    • 指定
    • 津貼
    • 專利
    • 技術
  • 第一階段:藥物簡介
    • 前臨床研究
    • 前臨床研究結果
    • 臨床試驗
    • 臨床結果
    • 策略性開發
    • 指定
    • 津貼
    • 專利
    • 技術
  • 前臨床:藥物簡介
    • 前臨床研究
    • 前臨床研究結果
    • 策略性開發
    • 指定
    • 津貼
    • 專利
    • 技術
  • 藥物研發:藥物簡介
    • 前臨床研究
    • 前臨床研究結果
    • 策略性開發
    • 指定
    • 津貼
    • 專利
    • 技術

第6章 臨床試驗分析

  • 臨床試驗:各地區
  • 臨床試驗:各檢測狀況

第7章 競爭環境

  • 主要企業的基準
  • SWOT分析

第8章 企業簡介

  • 產業概要
  • 提供產品與服務

第9章 附錄

目錄

IL-6 inhibitors currently exhibits a growing pipeline with approximately 18 active drug candidates, P&S Market Research

IL-6 inhibitors therapeutics pipeline in 2017

The study analyzed that the IL-6 inhibitors therapeutics pipeline comprises approximately 18 active drug candidates in different stages of development. Interleukin-6 inhibitors acts on the IL-6 receptor. IL-6 receptors belong to a group of cytokine receptors that are expressed by leukocytes and plays an important role in the functioning of the immune system. It has a characteristic role in systemic inflammation in numerous disease conditions, including rheumatoid arthritis, and psoriatic arthritis.

Insights on pipeline segments

According to the research findings, most of the drug candidates of the IL-16 inhibitors are being developed as the monoclonal antibody.

Positive Clinical Results of IL-6 Inhibitors Therapeutics Candidates

The positive clinical results from IL-6 inhibitors drug candidates have been driving the pipeline growth. GlaxoSmithKline plc presented results from two pivotal Phase III studies (NCT01606761; NCT02019472) evaluating subcutaneous sirukumab. In both the studies, sirukumab met the primary endpoint showing significant improvement in the signs and symptoms of moderately to severely active rheumatoid arthritis compared to placebo.

Various collaborations for IL-6 Inhibitors therapeutics drug development

In January 2017, Tiziana Life Sciences plc acquired an exclusive world-wide license for NI-1201, a fully human anti-IL-6R monoclonal antibody (mAb), from Novimmune SA. In exchange for the exclusive license from Novimmune SA, Tiziana Life Sciences plc agreed to an upfront cash payment, milestone payments, and a royalty on future sales.

Some of the key players developing drugs for the treatment of IL-6 inhibitors therapeutics include GlaxoSmithKline plc, Chugai Pharmaceutical Co., Ltd., Vitaeris Inc. and others.

IL-6 Inhibitors Therapeutics Pipeline Analysis

By Phase

By Molecule Type

By Route of Administration

By Company

Table of Content

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Definition
  • 1.3 Research Scope
  • 1.4 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
  • 2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

  • 4.1 Overview
  • 4.2 Key Drivers
  • 4.3 Key Barriers
  • 4.4 Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis
    • 4.4.1 Pipeline Analysis by Phase
    • 4.4.2 Pipeline Analysis by Molecule Type
    • 4.4.3 Pipeline Analysis by Route of Administration
    • 4.4.4 Pipeline Analysis by Company

Chapter 5. Interleukin-6 (IL-6) Inhibitors Therapeutics Pipeline Analysis by Phase (2017)

  • 5.1 Filed: Drug profiles
    • 5.1.3 Pre-Clinical Study
    • 5.2.2 Pre-Clinical Results
    • 5.2.3 Clinical Trials
    • 5.1.4 Clinical Results
    • 5.1.5 Strategic Development
    • 5.1.6 Designation
    • 5.1.7 Grants
    • 5.1.8 Patent
    • 5.1.9 Technology
  • 5.2 Phase III: Drug profiles
    • 5.2.1 Pre-Clinical Study
    • 5.2.2 Pre-Clinical Results
    • 5.2.3 Clinical Trials
    • 5.2.4 Clinical Results
    • 5.2.5 Strategic Development
    • 5.2.6 Designation
    • 5.2.7 Grants
    • 5.2.8 Patent
    • 5.2.9 Technology
  • 5.3 Phase II: Drug profiles
    • 5.2.1 Pre-Clinical Study
    • 5.2.2 Pre-Clinical Results
    • 5.2.3 Clinical Trials
    • 5.2.4 Clinical Results
    • 5.2.5 Strategic Development
    • 5.2.6 Designation
    • 5.2.7 Grants
    • 5.2.8 Patent
    • 5.2.9 Technology

Phase I: Drug profiles

    • 5.2.1 Pre-Clinical Study
    • 5.2.2 Pre-Clinical Results
    • 5.2.3 Clinical Trials
    • 5.2.4 Clinical Results
    • 5.2.5 Strategic Development
    • 5.2.6 Designation
    • 5.2.7 Grants
    • 5.2.8 Patent
    • 5.2.9 Technology
  • 5.4 Pre-Clinical: Drug profiles
    • 5.3.1 Pre-Clinical Study
    • 5.3.2 Pre-Clinical Results
    • 5.3.3 Strategic Development
    • 5.3.4 Designation
    • 5.3.5 Grants
    • 5.3.6 Patent
    • 5.3.7 Technology
  • 5.5 Discovery: Drug profiles
    • 5.3.1 Pre-Clinical Study
    • 5.3.2 Pre-Clinical Results
    • 5.3.3 Strategic Development
    • 5.3.4 Designation
    • 5.3.5 Grants
    • 5.3.6 Patent
    • 5.3.7 Technology

Chapter 6. Clinical Trials Analysis

  • 6.1 Clinical Trials by Region for IL-6 Inhibitors Therapeutics Pipeline
  • 6.2 Clinical Trials by Trial Status for IL-6 Inhibitors Therapeutics Pipeline

Chapter 7. Competitive Landscape

  • 7.1 Key Players Benchmarking for IL-6 Inhibitors Therapeutics Pipeline
  • 7.2 SWOT Analysis of IL-6 Inhibitors Therapeutics Pipeline
    • 7.2.1 Strengths
    • 7.2.2 Weaknesses
    • 7.2.3 Opportunities
    • 7.2.4 Threats

Chapter 8. Company Profiles

  • 8.1 Business Overview
  • 8.2 Product and Service Offerings

Chapter 9. Appendix

  • 9.1 Abbreviations
  • 9.2 Related Reports

LIST OF TABLES

  • PIPELINE ANALYSIS OF IL-6 INHIBITORS THERAPEUTICS, BY COMPANY (2017)
  • DESCRIPTION OF FILED DRUG CANDIDATES
  • CLINICAL TRIALS OF FILED DRUG CANDIDATES
  • DESCRIPTION OF PHASE III DRUG CANDIDATES
  • CLINICAL TRIALS OF PHASE III DRUG CANDIDATES
  • DESCRIPTION OF PHASE II DRUG CANDIDATES
  • CLINICAL TRIALS OF PHASE II DRUG CANDIDATES
  • DESCRIPTION OF PHASE I DRUG CANDIDATES
  • CLINICAL TRIALS OF PHASE I DRUG CANDIDATES
  • DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES
  • DESCRIPTION OF DISCOVERY DRUG CANDIDATES
  • COMPANIES- AT A GLANCE

LIST OF FIGURES

  • RESEARCH METHODOLOGY
  • SPLIT OF PRIMARY AND SECONDARY RESEARCH
  • BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT
  • BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY COMPANY TYPE
  • IL-6 INHIBITORS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
  • IL-6 INHIBITORS THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)
  • IL-6 INHIBITORS THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)
  • BREAKDOWN OF CLINICAL TRIALS, BY REGION
  • BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS
  • KEY PLAYERS BENCHMARKING
  • SWOT ANALYSIS
Back to Top